[New anti-arrhythmia drugs].
In this paper some of the new antiarrhythmic drugs are reviewed. The origin, electrophysiologic effects, mechanisms of action, pharmacokinetic properties, hemodynamic changes, clinical utilization with indications and contraindications as well as the collateral effects of: Verapamil Amiodarone, Aprindine, Encainide, Mexiletine and Tocainide are analyzed. A conclusion is drawn for each one of these drugs in accordance with the available information in the literature and the author's criteria and experience.
D000638:Amiodarone / Q000494:pharmacology; D000813:Anilides / Q000494:pharmacology; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D001073:Aprindine / Q000494:pharmacology; D001145:Arrhythmias, Cardiac / Q000188:drug therapy; D016700:Encainide; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008012:Lidocaine / Q000031:analogs & derivatives / Q000494:pharmacology; D008801:Mexiletine / Q000494:pharmacology; D016677:Tocainide; D014700:Verapamil / Q000494:pharmacology
D000813:Anilides; D000889:Anti-Arrhythmia Agents; D008801:Mexiletine; D016677:Tocainide; D001073:Aprindine; D008012:Lidocaine; D014700:Verapamil; D000638:Amiodarone; D016700:Encainide
Algunos aspectos de los nuevos medicamentos antiarrítmicos.